Published within
|«
«
|
...
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
About 1,200 US sales representatives at Wyeth have been notified this week that they are to lose their positions. The cuts come as part of a major company-wide restructuring program, announced nine weeks ago. Like many of its peers, Wyeth's US sales are struggling against increased competition from generic products: a trend which is forecast to intensify over the next five years.
Published By Datamonitor
|
28 Mar 2008 |
|
CommentWire
|
Wyeth's [WYE] pipeline is looking bare, particularly in women's health, with only two linked candidates in trials for osteoporosis/menopause. Recent agreements with biotech firms Tanox [TNOX] and Galapagos Genomics show the company is finally following other osteoporosis players' examples in a bid to remain in this lucrative market.
Published By Datamonitor
|
21 Nov 2003 |
|
CommentWire
|
A new study supports the possible link between breast cancer and hormone replacement therapy in post-menopausal women, fuelling safety concerns which have threatened the market since 2002. Datamonitor believes that with such a strong need for safer treatments in this indication, Wyeth's pipeline drug Aprela is well positioned to capture a significant share of the market.
Published By Datamonitor
|
10 Feb 2009 |
|
CommentWire
|
Wyeth has reported positive second quarter earnings, thanks in part to strong demand for the arthritis treatment Enbrel. With its launch in Japan already boosting sales, even with a drop in the drug's hard-sell marketing post-Vioxx, it is expected to remain well-positioned to carry the fight to Centocor's competing Remicade.
Published By Datamonitor
|
21 Jul 2005 |
|
CommentWire
|
Wyeth has released the findings of the study, which pooled together results of eight double-blind studies and compared Effexor XR to a leading serotonin selective re-uptake inhibitor. Although the drug's sales should be high it could suffer at the hands of strong competition from Lilly's duloxetine.<BR />
Published By Datamonitor
|
13 Dec 2002 |
|
CommentWire
|
Wyeth [WYE] has warned that its antidepressant Effexor (venlafaxine) is not effective for treating depression in children and teenagers, raising further concerns over the safety of prescribing antidepressants to children. However, due to the drug's ongoing success and growth it is unlikely this latest warning will have a significant effect on Effexor's sales.
Published By Datamonitor
|
08 Sep 2003 |
|
CommentWire
|
Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />
Published By Datamonitor
|
05 Jun 2003 |
|
CommentWire
|
Wyeth has discontinued a phase III trial of temsirolimus plus letrozole in metastatic post-menopausal hormone-receptor positive breast cancer. This is a significant blow for the company due to the loss of earnings potential in the congested but lucrative breast cancer market. However, temsirolimus remains under development for a number of other tumors, and so hope for the drug candidate remains.
Published By Datamonitor
|
23 Mar 2006 |
|
CommentWire
|
The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.
Published By Datamonitor
|
09 Jan 2009 |
|
CommentWire
|
Revenues at Wyeth have climbed despite declining sales of key products such as Premarin and Prevnar. Litigation expenses continue to impact the bottom line, but a cash injection resulting from the merger of Immunex and Amgen has improved the company's financial situation. There are signs the company could be ripe for consolidation once more.
Published By Datamonitor
|
30 Jan 2003 |
|
|«
«
|
...
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.